ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Ascendis Pharma A/S

Tuborg Boulevard 5
Hellerup 2900
45 70 22 22 44

Full Time Employees101

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael Wolff Jensen L.L.M.Chairman, Sr. VP, Gen. Counsel and Member of Exec. BoardN/AN/A1971
Mr. Jan Møller MikkelsenChief Exec. Officer, Pres, Member of Exec. Board and Exec. DirectorN/AN/A1960
Mr. Scott T. SmithChief Financial Officer and Sr. VPN/AN/A1974
Mrs. Lotte SønderbjergChief Admin. Officer, Sr. VP and Member of Exec. BoardN/AN/A1961
Dr. Grethe Rasmussen Ph.D.Sr. VP of Product Devel. and Member of Exec. BoardN/AN/A1962
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Corporate Governance

Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.